ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen Says Recent Sensipar Study Failed to Meet Primary Endpoint

By Mia Lamar Amgen Inc. (AMGN) said Friday that a study evaluating its Sensipar drug for effectiveness in reducing the risk of mortality and cardiovascular events in patients suffering from chronic kidney disease failed to meet its primary endpoint. Sensipar--which is marketed as Mimpara in Europe--was first approved in 2004 to treat thyroid problems in patients with kidney disease and cancer. The company recorded $808 million in global sales of the drug last year. Amgen said Friday it undertook the Phase 3 trial of Sensipar to discover whether the drug could positively impact the high rates of mortality and incidences like heart failure experienced by patients with chronic kidney disease that are receiving dialysis. Results, however, were not statistically significant, Amgen said. The company noted analyses from the study are ongoing and will be submitted for presentation at a major medical meeting later this year. Amgen, the biggest stand-alone biotechnology company, has been pursuing deals to bolster its research-and-development pipeline as sales growth slows for older drugs. Shares were recently off 26 cents to $68.84. Write to Mia Lamar at mia.lamar@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
08/27/201520:00:00FDA Approves Amgen's Cholesterol-Lowering Drug Repatha -- Update
08/27/201519:20:00FDA Approves New Amgen Cholesterol Drug
08/27/201518:40:00FDA Approves Amgen's Repatha Cholesterol Drug
08/27/201517:50:00FDA Approves Amgen's New Cholesterol-Lowering Medication Repatha™...
08/25/201509:45:00U.S. Hot Stocks: Hot Stocks to Watch
08/25/201509:40:00Amgen Files for U.S. Approval of Therapy for Dialysis Patients
08/25/201509:32:00Amgen Files for U.S. Approval of Therapy for Dialysis Patients
08/25/201509:15:00Amgen To Present New Long-Term Repatha™ (Evolocumab) Data Analysis A...
08/25/201509:00:00Amgen Submits New Drug Application For Novel Intravenous Calcimimetic...
08/20/201517:59:39Statement of Changes in Beneficial Ownership (4)
08/18/201514:40:00Amgen Reaches $71 Million Settlement With States
08/18/201514:25:00Amgen Reaches $71 Million Settlement With States Related to Promotion...
08/18/201513:01:00Press Release: AG Jepsen: Connecticut Joins $71 Million Multistate...
08/18/201512:47:00Press Release: Amgen to Pay $71 Million for Improper Drug Marketing...
08/18/201509:00:00Amgen And University Of California, Berkeley Announce Multi-Year...
08/06/201517:22:58Amended Quarterly Report (10-q/a)
08/06/201516:49:23Statement of Changes in Beneficial Ownership (4)
08/06/201508:51:21India Shares Edge Higher
08/05/201506:17:16Quarterly Report (10-q)
08/04/201518:45:24Statement of Changes in Beneficial Ownership (4)

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad